CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Mitigating time toxicity in lymphoma and multiple myeloma.
Mitigating time toxicity in lymphoma and multiple myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
肿瘤学中的“时间毒性”是指频繁的医疗相关互动可能干扰患者福祉。本综述探讨非霍奇金淋巴瘤和多发性骨髓瘤中时间毒性的多种表现，并讨论其对患者共同决策的影响。例如，时间毒性可能影响滤泡性淋巴瘤患者选择化学免疫治疗还是来那度胺-利妥昔单抗。在骨髓瘤中，它可能影响蛋白酶体抑制剂和双膦酸盐的最佳给药方案。在两种恶性肿瘤中，时间毒性谱的差异是CAR-T 细胞疗法和双特异性抗体的重要区别。本综述概述将时间毒性作为临床试验终点进行测量的挑战，同时讨论其在标准照护和临床试验中对患者照护的意义。全文还介绍了在不影响疗效或安全性的前提下减少淋巴瘤和骨髓瘤治疗时间毒性的策略。
The concept of time toxicity in oncology refers to the presence of frequent healthcare-related interactions that can interfere with patient well-being. In this review, we examine several manifestations of time toxicity in non-Hodgkin lymphoma and multiple myeloma and discuss their impact on decision-making with patients.
For example, time toxicity may influence the choice of chemoimmunotherapy versus lenalidomide-rituximab in follicular lymphoma. In myeloma, it may inform the optimal dosing schedule for proteasome inhibitors and bisphosphonates. In both malignancies, varying time toxicity profiles are a key distinction between chimeric antigen receptor T-cell therapies and bispecific antibodies.
We outline the challenges with measuring time toxicity as a trial endpoint but discuss its importance as a consideration for patient care, both in standard-of-care settings and in clinical trials. Throughout the review, we highlight strategies to lower the time toxicity of therapies in lymphoma and myeloma without compromising their efficacy or patient safety.
MEMBER ACCOUNT
登录成功会直接打开下一页。
